British Journal of Haematology · 1993 · 70 citations · 27 references
MedicineGeneticsHematologyCytogeneticsHematopathologyImmunogeneticsBone Marrow PathologyClinical CytogeneticsHematologic MalignanciesHematologic PathologyMyelodysplastic SyndromesChronic Myelomonocytic LeukemiaPluripotent Stem Cell DifferentiationRefractory Myelodysplastic SyndromeRestriction Fragment Length Polymorphism Analysis
Restriction fragment length polymorphisms (RFLP) of the X-chromosome genes phosphoglycerate kinase (PGK) and hypoxanthine phorphoribosyltransferase (HPRT) were used to determine the clonal nature of myelodysplastic syndromes (MDS) in 22 patients. These included eight with refractory anaemia (RA), four with RA with ring sideroblasts (RARS), six with RA with an excess of blasts (RAEB), three with RAEB in transformation (RAEB-T), and one with chronic myelomonocytic leukaemia (CMML). Monoclonal X-inactivation patterns were observed in 19/22 patients. The remaining three cases, one each with RA, RARS and RAEB, were of polyclonal composition. Separated T-lymphocyte and granulocyte fraction analyses in six patients of the former cases revealed that T-lymphocyte as well as granulocyte fractions showed a monoclonal pattern of X-inactivation. These results support the view that the majority of MDS arise from a pluripotent stem cell capable of myeloid and lymphoid differentiation.
27
Proposals for the classification of the myelodysplastic syndromes
John M. Bennett, Daniel Catovsky, MT Daniel et al. · British Journal of Haematology · 1982 · 3.7K citations
Medicine, Hematology, Pathology +12
P. J. Fialkow · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 1976 · 653 citations
Medicine, Cancer Biology, Oncology +14
Clonal analysis using recombinant DNA probes from the X-chromosome.
Bert Vogelstein, Eric R. Fearon, Stanley R. Hamilton et al. · PubMed · 1987 · 433 citations
Evidence for a multistep pathogenesis of chronic myelogenous leukemia
PJ Fialkow, PJ Martin, Vesna Najfeld et al. · Blood · 1981 · 329 citations · Full text
Medicine, Hematology, Oncology +13